Navigation Links
Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
Date:5/4/2010

EMERYVILLE, Calif., May 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the first quarter of fiscal year 2010 ended March 31, 2010 on Tuesday, May 11, 2010. The Company will conduct a conference call and webcast to review the financial results on Tuesday, May 11, 2010 at 5:00 p.m. ET.

Interested parties can access the call by dialing (877) 317-6789 or (412) 317-6789, or can listen via a live internet webcast, which can be found at http://bionovo.com/investors/events. A replay of the call will be available via webcast at http://bionovo.com/investors/events or by playback at (877) 344-7529 or (412) 317-0088, conference code 440464, through May 14, 2010.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
2. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
3. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
4. Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
5. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
6. Upgrade to Advanced Photon Source Announced by DOE
7. PolyTouch Medical Ltd. Announces the Submission of a Premarket Application for PatchAssist - an Innovative Mesh Deployment and Placement Device for Laparoscopic Hernia Repair
8. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
9. Scotland Announces New Life Science Leadership and Investments at BIO 2010
10. Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration
11. Knome Announces KnomeDISCOVERY Research Awards Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... A colony ... among its cells and tissues by delivering pollen and nectar containing nutrients necessary for ... means to stay healthy. , Many recent indicators point to a decline in honey ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer ... financing in the amount of $6 million. An investment vehicle affiliated with HighCape ... , The Series B funding will enable Cybrexa to complete the build-out of ...
(Date:6/14/2017)... ... 2017 , ... Slone Partners welcomed a panel of premier ... search firm, “Building Value in Precision Medicine: Can We Overcome the Obstacles?” , ... an open discussion with expert panelists Troy Cox, CEO of Foundation Medicine, Barbara ...
(Date:6/14/2017)... ... June 14, 2017 , ... The newest company to ... therapeutic antibodies using rabbits that express human genes. ATGC, a spin out of the ... in 2015, ATGC is a translational genomics company. Its founders are among the ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):